View ValuationPeptiDream 将来の成長Future 基準チェック /06PeptiDream利益と収益がそれぞれ年間1.8%と3.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19% 1.7%なると予測されています。主要情報1.8%収益成長率1.75%EPS成長率Biotechs 収益成長0%収益成長率3.4%将来の株主資本利益率18.97%アナリストカバレッジGood最終更新日16 Jan 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 01PeptiDream Inc. to Report Q2, 2026 Results on Aug 05, 2026PeptiDream Inc. announced that they will report Q2, 2026 results on Aug 05, 2026お知らせ • Apr 21PeptiDream Inc. Announces Initiation Of Phase 1 Clinical Trial Of AK1940 by its Collaboration Partner Asahi Kasei TherapeuticsPeptiDream Inc. announced that Asahi Kasei Therapeutics its collaboration partner, has initiated a Phase 1 clinical trial1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered through a research collaboration between the two companies using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®)2. AK1940 showed potent inhibitory activity and high selectivity for TNFR1 and exhibited efficacy in animal models of inflammatory disease, supporting its potential for the treatment of a broad range of autoimmune diseases. PeptiDream and Asahi Kasei Therapeutics entered into a collaborative research and development agreement in March 2016, under which the two companies have advanced the discovery of macrocyclic peptides using PeptiDream’s PDPS® technology. Asahi Kasei Therapeutics focuses its drug discovery and development efforts on disease areas including autoimmune diseases, severe infections, transplantation, kidney diseases, and orthopedic conditions. AK1940 is well aligned with Asahi Kasei Therapeutics’ R&D strategy and is expected to contribute to the medium- to long-term growth of the company’s pharmaceuticals business. With the initiation of the Phase 1 trial, PeptiDream will receive a milestone payment (amount undisclosed). Furthermore, PeptiDream is entitled to receive future clinical milestone payments, as well as royalties based on sales after launch.お知らせ • Mar 23PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)お知らせ • Feb 16+ 1 more updatePeptiDream Inc., Annual General Meeting, Mar 25, 2026PeptiDream Inc., Annual General Meeting, Mar 25, 2026.お知らせ • Dec 18PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of PsoriasisPeptiDream Inc. announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio - a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) - at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life. The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today's approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream's oral IL17 macrocyclic peptide is designed to change this paradigm--offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease. Key Highlights of the Program: Potent Orally Bioavailable Macrocyclic Peptide: Engineered for high-affinity and stability to achieve oral bioavailability and biologic-like potency. Inhibits Critical IL-17 Isoforms: Designed to inhibit not only IL-17A/A, IL-17A/F, but also IL-17F/F, associated with deeper and more durable clinical responses. Enhanced Tissue Penetration: The macrocyclic peptide candidate's small size enables improved distribution and potential for superior tissue-localized activity. Broad Therapeutic Opportunity: An oral therapy with the potential to treat a broad range of IL17-mediated diseases, unlocking new monotherapy and combination therapy approaches. PeptiDream's Oral dual IL-17A andIL-17F inhibitor was discovered using its proprietary PDPS®? technology and optimized for potency and oral bioavailability. In an IL-17 in vivo challenge model, oral dosing of peptide significantly reduced CXCL1 levels to the same extent as IV administration of an approved IL-17 biologic. Notably, greater skin distribution versus plasma was observed at 24 hours--a key differentiator over current biologics. Building on these encouraging results, PeptiDream is advancing the program into IND-enabling studies with a view toward clinical trials, while exploring strategic partnerships to accelerate global development and deliver a best-in-class oral therapy for autoimmune disease patients worldwide.お知らせ • Dec 03PeptiDream Inc. to Report Fiscal Year 2025 Results on Feb 16, 2026PeptiDream Inc. announced that they will report fiscal year 2025 results on Feb 16, 2026お知らせ • Oct 15PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA- I&T for Prostate Cancer in JapanPeptiDream Inc., PDRadiopharma Inc. and Curium Group announced that a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64Cu-PSMA- I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair, 177Lu-PSMA-I &T. The development is conducted under the strategic collaboration between PDRadiopharma and Curium aiming at advancing innovative radiopharmaceuticals for prostate cancer in Japan. The open-label, single-arm Phase 2 study will evaluate the sensitivity, specificity, and safety of 64Cu-PSMA- me&T. The trial will enroll approximately 70 patients who have been newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and are scheduled for prostatectomy with pelvic lymph node dissection. This study is being conducted as a registrational trial in Japan and will utilize bridging data from Curium's ongoing global clinical trials. In parallel, a clinical trial for 177Lu-PSMA- I& T as a therapeutic agent is being planned to evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).お知らせ • Sep 27PeptiDream Inc. to Report Q3, 2025 Results on Nov 12, 2025PeptiDream Inc. announced that they will report Q3, 2025 results on Nov 12, 2025お知らせ • May 31PeptiDream Inc. to Report Q2, 2025 Results on Aug 06, 2025PeptiDream Inc. announced that they will report Q2, 2025 results on Aug 06, 2025お知らせ • Mar 30National Cancer Center Hospital East and PeptiDream Inc. Announces New Radiopharmaceuticals for Renal Cell CarcinomaNational Cancer Center Hospital East and PeptiDream Inc. announced promising results from the first-in-human imaging trial of 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CA9), for patients with clear cell renal cell carcinoma (ccRCC). This trial, which was conducted at the NCC Hospital East in collaboration started from November 2023, aims for the early application of radiopharmaceuticals targeting CA9. The results showed that 64Cu-PD-327 66 effectively diagnosed tumors and in addition, calculations replacing 64Cu with 225Ac suggest that the absorbed dose in the tumor was 105.5+-55.8 mGy/MBq, which is expected to be sufficient for therapeutic effect. These findings were presented at the ASCO Genitourinary Cancers Symposium 2025 held in February 2025. In this trial, Cu-PD-32766, which was manufactured using NCC Hospital’s Cu production technologies and EPOC’s radiopharmaceuticals manufacturing technologies, was administered to five patients with newly diagnosed, relapsed or suspected relapsed ccRCC at NCC Hospital East. The safety, pharmacokinetics and dosimetry of PET/CT imaging using Cu-PD-32766 were evaluated. The effective dose for whole body by administration of Cu-PD-32766 was 0.102±0.0361 mSv/MBq and no serious side effects or adverse events were observed. Accumulation of Cu-PD-32766 in tumor lesions was confirmed by PET imaging within 5 minutes after administration, with positive rate of over 95% of lesions diagnosed by CT imaging. Clear PET images of tumor lesions were obtained from 5 minutes to 24 hours post-administration. The blood concentration of Cu-PD-32766 rapidly decreased within 5 minutes after administration, confirming good clearance. These results suggest the potential utility of Cu-PD-32766 as a diagnostic agent for ccRCC. Furthermore, calculations replacing Cu with the therapeutic radionuclide Ac suggest that the absorbed dose in the tumor was 105.5±55.8 mGy/MBq, which is expected to be sufficient for therapeutic effects. This trial investigated the potential application of Cu-PD-32766 as a diagnostic agent by evaluating safety, pharmacokinetics and whole-body absorbed dose. The results also suggest the potential theranostic application of PD-32766 by using both diagnostic and therapeutic radionuclides such as Ac. By evaluating the pharmacokinetics and targeted accumulation in tumors with a minimal dose administered to patients, this trial is anticipated to contribute to accelerating subsequent clinical development of PD-32766. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc., PeptiDream’s wholly owned subsidiary.お知らせ • Feb 13PeptiDream Inc., Annual General Meeting, Mar 27, 2025PeptiDream Inc., Annual General Meeting, Mar 27, 2025.お知らせ • Dec 12PeptiDream Inc. Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric CancerPeptiDream Inc. announced its second wholly-owned radiopharmaceutical development candidate arising from the company's ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ("PD-29875") is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ("CLDN18.2"), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues. CLDN18.2 is expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer, biliary cancer, genitourinary tract cancers, and colorectal cancer, and others. PD-29875 was discovered using PeptiDream's proprietary PDPS technology and further optimized at PeptiDream with in vivo imaging and efficacy studies conducted at PDRadiopharma, wholly owned subsidiary. PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer. The paired diagnostic imaging agent, which consists of the same peptide and chelator as the therapeutic, will enable to screen and identify patients, both in clinical trials and in clinical practice, who have CLDN18.2 expressing tumors that are most likely to have a favorable clinical response from PD-29875 treatment. PeptiDream is previously planning to initiate human Ph0 imaging studies of 64Cu-PD-29875 in 2025, prior to the start of a Phase 1 study. Gastric cancer is the 5th most common cancer in and the 4th leading cause of cancer death worldwide in 2020, representing 7% of all global cancer diagnoses, with an approximate 5-year survival rate of 32% (worldwide an estimated 1.1 million people were diagnosed with gastric cancer in 2020, with 770,000 deaths), with the incidence expected to increase to 1.8 million new cases per year by 2040.お知らせ • Dec 03PeptiDream Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025PeptiDream Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025お知らせ • Nov 12PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd.PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024. PeptiDream Inc. (TSE:4587) completed the acquisition of an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024.業績と収益の成長予測BMV:4587 N - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202749,40315,48515,98914,770412/31/202643,51311,86014,37113,197812/31/202540,26310,71413,84213,280812/31/202447,81417,22717,10510,07089/30/202447,77317,11525,06827,078N/A6/30/202455,41921,689-780992N/A3/31/202427,9742,4411,2282,760N/A12/31/202328,7123,03511,05212,420N/A9/30/202338,18711,2819,21310,512N/A6/30/202331,2547,9567,3978,696N/A3/31/202331,3968,1353,7487,663N/A12/31/202226,8527,554-4,057-82N/A9/30/202212,81157-5,082-1,376N/A6/30/202211,5111,705-2,4831,687N/A3/31/20228,3262,3414211,929N/A12/31/20219,3663,6065,4406,655N/A9/30/202115,6077,1105,2296,447N/A6/30/202111,4494,3294,8695,368N/A3/31/202112,7435,2265,6436,111N/A12/31/202011,6774,4481,1461,733N/A12/31/20192,075-977207484N/A6/30/20197,2172,7704,2864,481N/A6/30/20186,4272,335N/A1,023N/A3/31/20184,616895N/A623N/A9/30/20174,271962N/A517N/A6/30/20174,8961,891N/A1,531N/A3/31/20173,064769N/A1,095N/A12/31/20164,4571,685N/A2,338N/A9/30/20164,7351,823N/A2,844N/A6/30/20164,3281,581N/A1,533N/A3/31/20164,6201,976N/A2,027N/A12/31/20153,1211,203N/A1,216N/A9/30/20152,7221,063N/A834N/A6/30/20152,4741,004N/A1,386N/A3/31/201575746N/A85N/A12/31/201473967N/A74N/A9/30/2014786118N/A165N/A6/30/2014819149N/A72N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4587 Nの予測収益成長率 (年間1.8% ) は 貯蓄率 ( 8.1% ) を下回っています。収益対市場: 4587 Nの収益 ( 1.8% ) MX市場 ( 8.8% ) よりも低い成長が予測されています。高成長収益: 4587 Nの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 4587 Nの収益 ( 3.4% ) MX市場 ( 6.4% ) よりも低い成長が予測されています。高い収益成長: 4587 Nの収益 ( 3.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4587 Nの 自己資本利益率 は、3年後には低くなると予測されています ( 19 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/02/02 21:19終値2024/11/05 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PeptiDream Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Shan HeBernsteinHidemaru YamaguchiCitigroup IncKazuaki HashiguchiDaiwa Securities Co. Ltd.11 その他のアナリストを表示
お知らせ • Jun 01PeptiDream Inc. to Report Q2, 2026 Results on Aug 05, 2026PeptiDream Inc. announced that they will report Q2, 2026 results on Aug 05, 2026
お知らせ • Apr 21PeptiDream Inc. Announces Initiation Of Phase 1 Clinical Trial Of AK1940 by its Collaboration Partner Asahi Kasei TherapeuticsPeptiDream Inc. announced that Asahi Kasei Therapeutics its collaboration partner, has initiated a Phase 1 clinical trial1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered through a research collaboration between the two companies using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®)2. AK1940 showed potent inhibitory activity and high selectivity for TNFR1 and exhibited efficacy in animal models of inflammatory disease, supporting its potential for the treatment of a broad range of autoimmune diseases. PeptiDream and Asahi Kasei Therapeutics entered into a collaborative research and development agreement in March 2016, under which the two companies have advanced the discovery of macrocyclic peptides using PeptiDream’s PDPS® technology. Asahi Kasei Therapeutics focuses its drug discovery and development efforts on disease areas including autoimmune diseases, severe infections, transplantation, kidney diseases, and orthopedic conditions. AK1940 is well aligned with Asahi Kasei Therapeutics’ R&D strategy and is expected to contribute to the medium- to long-term growth of the company’s pharmaceuticals business. With the initiation of the Phase 1 trial, PeptiDream will receive a milestone payment (amount undisclosed). Furthermore, PeptiDream is entitled to receive future clinical milestone payments, as well as royalties based on sales after launch.
お知らせ • Mar 23PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)
お知らせ • Feb 16+ 1 more updatePeptiDream Inc., Annual General Meeting, Mar 25, 2026PeptiDream Inc., Annual General Meeting, Mar 25, 2026.
お知らせ • Dec 18PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of PsoriasisPeptiDream Inc. announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio - a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) - at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life. The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today's approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream's oral IL17 macrocyclic peptide is designed to change this paradigm--offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease. Key Highlights of the Program: Potent Orally Bioavailable Macrocyclic Peptide: Engineered for high-affinity and stability to achieve oral bioavailability and biologic-like potency. Inhibits Critical IL-17 Isoforms: Designed to inhibit not only IL-17A/A, IL-17A/F, but also IL-17F/F, associated with deeper and more durable clinical responses. Enhanced Tissue Penetration: The macrocyclic peptide candidate's small size enables improved distribution and potential for superior tissue-localized activity. Broad Therapeutic Opportunity: An oral therapy with the potential to treat a broad range of IL17-mediated diseases, unlocking new monotherapy and combination therapy approaches. PeptiDream's Oral dual IL-17A andIL-17F inhibitor was discovered using its proprietary PDPS®? technology and optimized for potency and oral bioavailability. In an IL-17 in vivo challenge model, oral dosing of peptide significantly reduced CXCL1 levels to the same extent as IV administration of an approved IL-17 biologic. Notably, greater skin distribution versus plasma was observed at 24 hours--a key differentiator over current biologics. Building on these encouraging results, PeptiDream is advancing the program into IND-enabling studies with a view toward clinical trials, while exploring strategic partnerships to accelerate global development and deliver a best-in-class oral therapy for autoimmune disease patients worldwide.
お知らせ • Dec 03PeptiDream Inc. to Report Fiscal Year 2025 Results on Feb 16, 2026PeptiDream Inc. announced that they will report fiscal year 2025 results on Feb 16, 2026
お知らせ • Oct 15PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA- I&T for Prostate Cancer in JapanPeptiDream Inc., PDRadiopharma Inc. and Curium Group announced that a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64Cu-PSMA- I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair, 177Lu-PSMA-I &T. The development is conducted under the strategic collaboration between PDRadiopharma and Curium aiming at advancing innovative radiopharmaceuticals for prostate cancer in Japan. The open-label, single-arm Phase 2 study will evaluate the sensitivity, specificity, and safety of 64Cu-PSMA- me&T. The trial will enroll approximately 70 patients who have been newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and are scheduled for prostatectomy with pelvic lymph node dissection. This study is being conducted as a registrational trial in Japan and will utilize bridging data from Curium's ongoing global clinical trials. In parallel, a clinical trial for 177Lu-PSMA- I& T as a therapeutic agent is being planned to evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).
お知らせ • Sep 27PeptiDream Inc. to Report Q3, 2025 Results on Nov 12, 2025PeptiDream Inc. announced that they will report Q3, 2025 results on Nov 12, 2025
お知らせ • May 31PeptiDream Inc. to Report Q2, 2025 Results on Aug 06, 2025PeptiDream Inc. announced that they will report Q2, 2025 results on Aug 06, 2025
お知らせ • Mar 30National Cancer Center Hospital East and PeptiDream Inc. Announces New Radiopharmaceuticals for Renal Cell CarcinomaNational Cancer Center Hospital East and PeptiDream Inc. announced promising results from the first-in-human imaging trial of 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CA9), for patients with clear cell renal cell carcinoma (ccRCC). This trial, which was conducted at the NCC Hospital East in collaboration started from November 2023, aims for the early application of radiopharmaceuticals targeting CA9. The results showed that 64Cu-PD-327 66 effectively diagnosed tumors and in addition, calculations replacing 64Cu with 225Ac suggest that the absorbed dose in the tumor was 105.5+-55.8 mGy/MBq, which is expected to be sufficient for therapeutic effect. These findings were presented at the ASCO Genitourinary Cancers Symposium 2025 held in February 2025. In this trial, Cu-PD-32766, which was manufactured using NCC Hospital’s Cu production technologies and EPOC’s radiopharmaceuticals manufacturing technologies, was administered to five patients with newly diagnosed, relapsed or suspected relapsed ccRCC at NCC Hospital East. The safety, pharmacokinetics and dosimetry of PET/CT imaging using Cu-PD-32766 were evaluated. The effective dose for whole body by administration of Cu-PD-32766 was 0.102±0.0361 mSv/MBq and no serious side effects or adverse events were observed. Accumulation of Cu-PD-32766 in tumor lesions was confirmed by PET imaging within 5 minutes after administration, with positive rate of over 95% of lesions diagnosed by CT imaging. Clear PET images of tumor lesions were obtained from 5 minutes to 24 hours post-administration. The blood concentration of Cu-PD-32766 rapidly decreased within 5 minutes after administration, confirming good clearance. These results suggest the potential utility of Cu-PD-32766 as a diagnostic agent for ccRCC. Furthermore, calculations replacing Cu with the therapeutic radionuclide Ac suggest that the absorbed dose in the tumor was 105.5±55.8 mGy/MBq, which is expected to be sufficient for therapeutic effects. This trial investigated the potential application of Cu-PD-32766 as a diagnostic agent by evaluating safety, pharmacokinetics and whole-body absorbed dose. The results also suggest the potential theranostic application of PD-32766 by using both diagnostic and therapeutic radionuclides such as Ac. By evaluating the pharmacokinetics and targeted accumulation in tumors with a minimal dose administered to patients, this trial is anticipated to contribute to accelerating subsequent clinical development of PD-32766. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc., PeptiDream’s wholly owned subsidiary.
お知らせ • Feb 13PeptiDream Inc., Annual General Meeting, Mar 27, 2025PeptiDream Inc., Annual General Meeting, Mar 27, 2025.
お知らせ • Dec 12PeptiDream Inc. Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric CancerPeptiDream Inc. announced its second wholly-owned radiopharmaceutical development candidate arising from the company's ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ("PD-29875") is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ("CLDN18.2"), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues. CLDN18.2 is expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer, biliary cancer, genitourinary tract cancers, and colorectal cancer, and others. PD-29875 was discovered using PeptiDream's proprietary PDPS technology and further optimized at PeptiDream with in vivo imaging and efficacy studies conducted at PDRadiopharma, wholly owned subsidiary. PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer. The paired diagnostic imaging agent, which consists of the same peptide and chelator as the therapeutic, will enable to screen and identify patients, both in clinical trials and in clinical practice, who have CLDN18.2 expressing tumors that are most likely to have a favorable clinical response from PD-29875 treatment. PeptiDream is previously planning to initiate human Ph0 imaging studies of 64Cu-PD-29875 in 2025, prior to the start of a Phase 1 study. Gastric cancer is the 5th most common cancer in and the 4th leading cause of cancer death worldwide in 2020, representing 7% of all global cancer diagnoses, with an approximate 5-year survival rate of 32% (worldwide an estimated 1.1 million people were diagnosed with gastric cancer in 2020, with 770,000 deaths), with the incidence expected to increase to 1.8 million new cases per year by 2040.
お知らせ • Dec 03PeptiDream Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025PeptiDream Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025
お知らせ • Nov 12PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd.PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024. PeptiDream Inc. (TSE:4587) completed the acquisition of an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024.